Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

Regeneron Product REGN-EB3 Saving Lives
Regeneron (REGNannounced that an independent monitoring board ended its investigational product REGN-EB3 trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals (MAPP) in saving the lives in . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.